CClinicalTrials.gg
CompletedNCT03258684HYVCTTSSSUpdated Mar 12, 2019

Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock

An interventional study of Hydrocortisone, Vitamin C, and Thiamine and Normal saline in Sepsis, sponsored by Zhujiang Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-12.

Sponsored by Zhujiang Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In this prospective clinical study, the investigators compare the outcome and clinical course of consecutive septic participants treated with intravenous vitamin C, hydrocortisone, and thiamine (treatment group) with a control group treated in the investigators' ICU. The primary outcome is hospital survival. A propensity score is generated to adjust the primary outcome.There is 70 participants in each group.

Read the detailed description

A prospective randomized controlled trial is conducted.One hundred and forty severe sepsis or septic shock participants admit to the Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University from September 2017.The participants are divided into control group ( n = 70 ) and treatment group ( n = 70 ).The participants in both groups are treated according to "2016 international guidelines for management of sepsis and septic shock",and the participants in treatment group receive intravenous vitamin C, hydrocortisone, and thiamine. The participants in control group receive normal saline.The patients' clinical and demographic data, including age, sex, admitting diagnosis, comorbidities, requirement for mechanical ventilation, use of vasopressors, daily urine output, fluid balance after 24 and 72 h, length of ICU stay (LOS),and laboratory data (serum creatinine, White Blood Cell (WBC), platelet count, total bilirubin, procalcitonin(PCT), and lactate levels), are recorded.The primary outcome is hospital survival. Secondary outcomes include duration of vasopressor therapy,requirement for renal replacement therapy in patients with Acute kidney injury (AKI), ICU LOS, and the change in serum procalcitonin and Sepsis-Related Organ Failure Assessment (SOFA score) over the first 72 h. Summary statistics are used to describe the clinical data and are presented as means±SD, medians and interquartile range, or percentages as appropriate.Statistical analysis is performed with NCSS 11 (NCSS Statistical Software) and SPSS Statistics version 24 (IBM).

02

Conditions studied

  • Sepsis

Keywords

  • corticosteroid
  • hydrocortisone
  • septic shock
  • thiamine
  • vitamin C
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • A primary diagnosis of sepsis or septic shock (the diagnoses of sepsis and septic shock are based on the 2016 the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)) and a procalcitonin (PCT) level≥2ng/mL.

Sepsis: Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.

Septic shock: Septic shock is a subset of sepsis in which underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality.

Exclusion criteria

Exclusion Criteria:

  • Patients \< 18 years of age, pregnant patients, and patients with limitations of care.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    vitamin C、hydrocortisone、thiamine

    Intravenous vitamin C (1.5 g every 6 h for 4 days or until ICU discharge), hydrocortisone (50 mg every 6 h for 7 days or until ICU discharge followed by a taper over 3 days), as well as intravenous thiamine (200 mg every 12 h for 4 days or until ICU discharge).

    Drug: Hydrocortisone, Vitamin C, and Thiamine

  • Placebo comparator
    normal saline

    Normal saline 500ml every day for 4 days,then 200ml every day for 3 days.

    Other: Normal saline

Interventions

  • DrugHydrocortisone, Vitamin C, and Thiamine

    Intervention

  • OtherNormal saline

    Placebo

05

What researchers measure

Primary outcomes

  1. hospital survival

    Time frame: Up to Day 14

Secondary outcomes

  1. duration of vasopressor therapy

    Time frame: Up to hour 72

  2. requirement for renal replacement therapy in participants with Acute kidney injury(AKI)

    Time frame: Up to Day 14

  3. ICU length of stay(LOS)

    Time frame: Up to Day 14

  4. the change in serum procalcitonin (PCT)

    Time frame: Up to hour 72

  5. Sepsis-Related Organ Failure Assessment(SOFA)score

    Time frame: Up to hour 96

06

Study locations

1 site
  • Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University
    Guangzhou, Guangdong 510282, China
07

References and documents

Publications

  • Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. Chest. 2017 Jun;151(6):1229-1238. doi: 10.1016/j.chest.2016.11.036. Epub 2016 Dec 6. PubMed 27940189 ↗
  • Chang P, Liao Y, Guan J, Guo Y, Zhao M, Hu J, Zhou J, Wang H, Cen Z, Tang Y, Liu Z. Combined Treatment With Hydrocortisone, Vitamin C, and Thiamine for Sepsis and Septic Shock: A Randomized Controlled Trial. Chest. 2020 Jul;158(1):174-182. doi: 10.1016/j.chest.2020.02.065. Epub 2020 Mar 31. PubMed 32243943 ↗

Related links

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03258684
Lead sponsor
Zhujiang Hospital
Responsible party
Sponsor
First posted
Aug 23, 2017
Start date
Sep 25, 2017
Primary completion
Feb 2, 2019
Completion
Feb 2, 2019
Last update
Mar 12, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion